Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | VNQI | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $50.76 |
52-Week Low | $10.24 | $43.26 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.50, up 0.38% with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF offers international real estate diversification with a low 0.12% expense ratio and attractive 4.6% dividend yield. Recent news highlights its cost advantage over competitors and institutional buying interest from Eagle Bay Advisors, which increased its stake by 95.7% in Q4 2025.
VNQI presents a compelling opportunity for yield-seeking investors seeking global real estate exposure at low cost, with recovery potential as global transaction volumes are expected to rise over 10% in 2026. Key risks include currency fluctuations, international economic volatility, and interest rate sensitivity. The ETF's valuation appears reasonable at 11.9x P/E and 0.9x P/B according to Seeking Alpha analysis from May 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
